Noncommunicable diseases, such as Alzheimer’s disease, breast and prostate cancer, are becoming increasingly prevalent in Western countries. To better elucidate the onset and evolution of these pathologies and ultimately design new preventive and therapeutic strategies, research activities focused on these biomedical areas have been supported by the European Union in the last two decades. While research has globally contributed increasing our understanding of the pathological mechanisms underlying these diseases, the failure rate in drug development still remains very high. Nowadays, it is important to monitor contribution to innovation and impact of funded research by means of defined indicators.